Reset all filters
01 1Bevacizumab+Rituximab
02 2Blank
Reset all filters
01 3Inactive
01 3Blank
Reset all filters
01 3Blank
Reset all filters
01 3Blank
Reset all filters
01 3Blank
Reset all filters
01 3Blank
01 3Blank
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 18615
Submission : 1993-03-22
Status : Inactive
Type : II
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 17814
Submission : 2004-10-25
Status : Inactive
Type : II
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 18728
Submission : 2005-09-02
Status : Inactive
Type : II
National Cancer Institute is a supplier offers 3 products (APIs, Excipients or Intermediates).
Find a price of Bevacizumab+Rituximab bulk offered by National Cancer Institute
Find a price of 2-CYANO-3, 12-DIOXOOLEANA-1, 9(11)-DIEN-28-OIC ACID (CDDO) bulk offered by National Cancer Institute
Find a price of HUMANIZED MIK-BETA-1 MONOCLONAL ANTIBODY bulk offered by National Cancer Institute